Empagliflozin for fluid buildup from cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have cirrhosis with ascites and are on a stable water-pill plan (spironolactone, and sometimes a loop diuretic) without needing a large belly-drain
- Your kidney function is good enough for the study (eGFR is 30 or higher)
- Your blood pressure is not too low (systolic is at least 100)
- Your bilirubin (direct bilirubin) is less than 3 mg/dL
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests whether empagliflozin improves kidney health and the function of the belly’s dialysis membrane in people with end-stage kidney disease who do peritoneal dialysis. It may help by changing how well the peritoneal dialysis system works and how the kidneys perform over time.
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
This trial tests whether dapagliflozin, a diabetes medicine that helps remove extra fluid through urine, can reduce fluid buildup in the belly (ascites) that doesn't improve with standard treatments. It is for people with advanced liver disease whose ascites keeps coming back quickly.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.